Brief: Herantis Pharma: Finnish Medicines Agency authorization of clinical study with Lymfactin

Herantis Pharma Oyj

13/11/2015 07:00

Nov 13 (Reuters) - Herantis Pharma Oyj  HRTIS.HE : 
    * Finnish Medicines Agency Fimea has authorized Herantis Pharma's first-in-man clinical 
study of Lymfactin for the treatment of breast-cancer associated lymphedema 
    * Patient recruitment in the clinical study is planned to begin in Finland in the first half 
of 2016 
 
     
Source text for Eikon:  ID:nHUG3rwc5m  
     
Further company coverage:  HRTIS.HE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48586983920;))